



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/965,551	09/27/2001	Muthiah Manoharan	ISIS-4847	3873

7590 02/14/2003

Woodcock Washburn Kurtz  
Mackiewicz & Norris LLP  
46th Floor  
One Liberty Place  
Philadelphia, PA 19103

[REDACTED] EXAMINER

SCHULTZ, JAMES

ART UNIT	PAPER NUMBER
1635	13

DATE MAILED: 02/14/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	09/965,551	MANOHARAN, MUTHIAH	
	<b>Examiner</b>	<b>Art Unit</b>	
	J. Douglas Schultz	1635	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on 21 January 2003.
- 2a) This action is FINAL.                    2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 28-30 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_\_ is/are allowed.
- 6) Claim(s) 28-30 is/are rejected.
- 7) Claim(s) \_\_\_\_\_ is/are objected to.
- 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) The proposed drawing correction filed on \_\_\_\_\_ is: a) approved b) disapproved by the Examiner.  
If approved, corrected drawings are required in reply to this Office action.
- 12) The oath or declaration is objected to by the Examiner.

#### Priority under 35 U.S.C. §§ 119 and 120

- 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some \* c) None of:  
 1. Certified copies of the priority documents have been received.  
 2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.
- 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  
a) The translation of the foreign language provisional application has been received.
- 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

#### Attachment(s)

- |   |  |
|---|--|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)                                | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____ . |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)            | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)  |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____. . | 6) <input type="checkbox"/> Other: _____ .                                   |

**DETAILED ACTION*****Response to Arguments***

1. The following rejection is a reiteration of that from the previous Office action. Said rejection is maintained against claims that were omitted in obvious error from the rejection mailed November 20, 2002. At Applicants directions from the communication dated January 21, 2003, claims 34-51 have been cancelled.
  
2. Claims 28- 30 stand rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for in vitro inhibition of ICAM transcripts, does not reasonably provide enablement for in vivo treatment or prevention of any disease associated with the undesired production of a protein, for reasons of record set forth in the Office action mailed June 5, 2002. Applicant's arguments filed September 3, 2002 have been fully considered but they are not persuasive.

Applicant's traversal of the rejection of claims 28-30 under 35 U.S.C. 112 1<sup>st</sup> paragraph enablement is based on the assertion that said rejection relied on a few select references that mischaracterize the state of the art by emphasizing the problems and failures over the successes achieved in the field. In support of this assertion, applicant provides references that demonstrate success in the use of antisense compounds in the whole animal. Applicant also argues that 35 U.S.C. 112 does not require the specification to resolve the unpredictabilities associated with the treatment and prevention of diseases as claimed. Applicant asserts that even if such a requirement existed under the law, that the specification enables the skilled artisan to carry out Applicant's method of providing treatment and prevention of diseases. In support of this,

Applicant points to the specification's example of the use of antisense oligonucleotides *in vitro*, which applicant asserts is a model for *in vivo* systems, and to the demonstration of *in vivo* injections of antisense compounds, which resulted in effective delivery and systemic distribution of said compounds.

These arguments are not adopted. Applicants assertion that the references provided "mischaracterize" the state of the art is unfounded. There is no evidence to indicate how or why the five review papers referenced in the Office action of May 5, 2002, and which demonstrate Applicants lack of enablement, mischaracterize the art; furthermore, Applicant has not provided any evidence that the respective authors mischaracterized the art in the first place. While Applicant's submitted references do show some of the successes seen in the field, the preponderance of evidence, as summarized in the review articles cited in the last Office action, indicates that using antisense to provide treatment or prevention of any disease is controversial and unpredictable, as indicated by Braasch in the rejection of the last Office action: "gene inhibition by antisense oligomers has not proven to be a robust or generally reliable technology. Many researchers are skeptical about the approach, and it has been suggested that many published studies are at least partially unreliable". Thus it is not surprising that the primary references cited in detail in Applicant's arguments all reference the novelty of demonstrating the successful use of antisense *in vivo*.

The considering the state of the art as a whole as required by *in re Wands*, it is noted that Applicants' submission of articles consists mostly of primary references, each of which describe the results of only one series of experiments; such primary research articles don't presume to indicate the state of the art as a whole. In contrast, the articles submitted by the examiner are all

Art Unit: 1635

review papers, whose function it is to distill a large volume of primary literature, such as those submitted by Applicant, and then to discuss and analyze problems, successes, trends and future directions. It is thus difficult to comprehend how the five review articles, whose function is essentially to characterize the state of the art, were actually mischaracterizing the state of the art during their review of anti-sense mediated gene inhibition. It is not argued that there have been irregular incidences of success in using antisense *in vivo*; however, the art of using antisense compounds successfully *in vivo* remains highly unpredictable, as indicated by Branch in the last Office action: "As is true of all pharmaceuticals, the value of a potential antisense drug can only be judged after its intended clinical use is known, and quantitative information about its dose-response curves and therapeutic index is available." When the primary literature supplied by Applicant is put in the context of the art as a whole, as has been done in the review articles cited in the previous Office action, it is clear that such primary references supplied by Applicant do not indicate that the state of the art of providing treatment and prevention of disease using antisense compounds and methods as claimed is at all predictable, and thus enabled.

Applicant also asserts that 35 U.S.C. 112 paragraph 1 does not require the specification to provide guidance in resolving known unpredictability that exists in Applicant's claimed invention. It is held that in considering the Wands factors, the requirement exists that guidance be given from either Applicant's specification or from the prior art or a combination thereof. If the prior art is not enabling, as has been previously established, then guidance must necessarily come from the specification.

Further, Applicant argues that even if such a requirement is made of the specification, that the *in vitro* example of ICAM inhibition and the *in vivo* study of the distribution of injected

Art Unit: 1635

antisense molecules provides enablement. This view is not adopted. While Applicant asserts that the *in vitro* example is a model of *in vivo* activity, it is reiterated that the primary reasons for lack of enablement of such treatment *in vivo* is due to problems with non-specific interactions of administered oligos with plasma and/or cellular proteins that it encounters before contacting its target, and to significant immune reactions to said administration, and finally to problems with target access itself, that is entering the cell and binding to the transcript so that inhibition occurs. The *in vitro* model does not allow for testing or resolution of these issues, and as such cannot provide proper guidance in these areas. The *in vivo* distribution studies suffer the same deficiencies; simply injecting the oligo and noting where it collected in the animal would not provide guidance as to whether the gene target was actually inhibited, let alone determine if treatment or prevention associated with that protein would ever be observed.

**THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.


Art Unit: 1635

Any inquiry concerning this communication or earlier communications from the examiner should be directed to J. Douglas Schultz whose telephone number is 703-308-9355. The examiner can normally be reached on 8:00-4:30 M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John L. LeGuyader can be reached on 703-308-0447. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3014 for regular communications and 703-305-3014 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

James Douglas Schultz, PhD  
February 12, 2003



A handwritten signature consisting of two loops. Inside the loops, the text "SEAN McGARRY" is written vertically, and "PRIMARY EXAMINER" is written below it. Below the loops, the number "1635" is written.